Arcadia Biosciences is expected to report third-quarter 2026 results in early November 2026, with consensus revenue near $2.4 million. Analysts expect a loss of roughly $0.46 per share, a narrower deficit than the prior quarter's reported loss.

Bluejay Diagnostics (NASDAQ: BJDX) is expected to report its third-quarter fiscal 2026 results around mid-November 2026. As a clinical-stage, pre-revenue medical diagnostics company, the report will center on net loss, cash burn, and balance sheet strength rather than revenue growth.

Oragenics is a pre-revenue, clinical-stage biotechnology company, so its third-quarter 2026 report is expected to show no product revenue, with investor focus falling on operating expenses, net loss per share, and cash runway. Because the company has no formal sell-side analyst coverage, the report is typically assessed on cost trends and balance-sheet health rather than revenue or earnings-per-share beats and misses.

Ernexa Therapeutics (ERNA) is expected to report third-quarter 2026 results for the period ended September 30, 2026, with an estimated release date around November 6, 2026. Wall Street consensus calls for a loss of $3.84 per share, with revenue expected to be $0, reflecting the company's preclinical-stage, non-revenue-generating status.

Creative Medical Technology Holdings (CELZ) is expected to report results for the third quarter of fiscal 2026, the period ended September 30, 2026, on or around November 6, 2026. Wall Street's consensus estimate calls for a net loss of roughly -$0.24 per share , a notably narrower loss than the -$0.41 per share reported in the prior quarter.

Mustang Bio reported a third-quarter 2026 net loss of $0.964 million, compared with a net loss of $0.468 million in the same period a year earlier. Basic and diluted loss per share from continuing operations widened to $0.14, up from $0.07 in the third quarter of 2025.

Kiora Pharmaceuticals (NASDAQ: KPRX) is expected to report third-quarter 2026 results before the market opens on November 6, 2026. Wall Street consensus points to a net loss of roughly -$0.38 per share for Q3 2026, with revenue expected at $0, reflecting the company's clinical-stage status.

Cheetah Net Supply Chain Service (NASDAQ: CTNT) is expected to report third-quarter 2026 results on or around Friday, November 6, 2026, with its earnings conference call scheduled for November 13, 2026. Wall Street consensus calls for a net loss of approximately $31.50 per share on revenue of roughly $600,000 for the quarter ended September 30, 2026.

Soligenix reported a net loss of $1.1 million, or $0.05 per share, for the third quarter of 2026, a meaningful improvement from $2.5 million, or $0.58 per share, in the same period a year earlier. The result came in well ahead of consensus expectations, which had projected a loss of approximately $0.12 per share.

Exicure, Inc. (XCUR) is expected to report third-quarter 2026 results in mid-November, though the exact date remains an estimate pending the company's confirmation. Because Exicure generates no product revenue, the report will center on cash reserves, operating losses, and the company's going-concern disclosure rather than top-line growth.

GEN Restaurant Group is expected to report third-quarter (Q3) 2026 results for the period ended September 30, 2026, with consensus estimates pointing to a loss of $0.06 per share on revenue of roughly $53.90 million. The report arrives during a strategic shift toward the faster-growing consumer packaged goods (CPG) business, which management now expects to reach $35 million to $40 million in annualized revenue.

SUNation Energy (SUNE) is expected to report third-quarter fiscal 2026 results in mid-November, following its calendar-year reporting schedule. The company's most recent quarter showed continued pressure: Q2 2026 revenue fell about 37.5% year over year to $8.16 million, with a net loss of $3.34 million.

Chicago Rivet & Machine reported a third-quarter 2026 net loss of $915,977, or $0.95 per share, reversing a modest profit of $67,572, or $0.07 per share, in the same period a year earlier. Net sales rose 2.3% year over year to $7,530,167, but higher costs and lower gross profit erased the benefit of the revenue gain.

Fusemachines reported its third quarter 2026 results, with revenue of approximately $1.84 million, up roughly 2.8% from the prior quarter. Adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization), a non-GAAP profitability measure, improved 39.2% quarter-over-quarter.

Orion Digital narrowed its net loss to C$3.1 million in Q3 2026, compared with C$4.5 million in the prior-year period. Total revenue held roughly flat at C$17.0 million, while adjusted EBITDA slipped 4% to C$1.9 million.

The Hain Celestial Group, Inc. (HAIN) is scheduled to report fiscal first quarter 2027 results before the market opens on Monday, November 9, 2026. Analysts expect an adjusted loss of roughly $0.04 per share on revenue near $283 million, a sharp year-over-year decline driven by the completed sale of its North American snacks business.

Avalon Holdings Corporation (AWX) reported third quarter 2026 net income attributable to common shareholders of $2.7 million , up from $1.9 million in the same period a year earlier. Basic earnings per share (EPS) rose to $0.69 in the third quarter of 2026, compared with $0.49 in the third quarter of 2025.

Greenland Technologies Holding Corporation (NASDAQ: GTEC) is expected to report its third quarter 2026 results on or around Friday, November 6, 2026, before the market opens, with a conference call scheduled for 9:30 AM ET. Wall Street consensus points to earnings per share (EPS) of $0.13 and revenue of approximately $24.60 million for the quarter.

Quantum BioPharma (QNTM) is expected to report its third-quarter 2026 results — the quarter ended September 30, 2026 — in mid-November, before the market opens. As a pre-revenue biopharmaceutical company, the quarter will be judged on operating losses, cash burn, and research-and-development (R&D) progress rather than sales.

Impact BioMedical is expected to report results for the third quarter of fiscal 2026 (the three months ended September 30, 2026) around November 17, 2026. The company carries minimal formal analyst coverage, so there is essentially no published revenue or EPS (earnings per share) consensus to anchor investor expectations.